Frontiers in Immunology (Apr 2023)
Corrigendum: Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
- Shuqun Li,
- Shuqun Li,
- Junyi Wu,
- Junyi Wu,
- Jiayi Wu,
- Jiayi Wu,
- Yangkai Fu,
- Zhenxin Zeng,
- Yinan Li,
- Han Li,
- Weijia Liao,
- Maolin Yan,
- Maolin Yan
Affiliations
- Shuqun Li
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Shuqun Li
- Department of Hepatobiliary Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
- Junyi Wu
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Junyi Wu
- Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China
- Jiayi Wu
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Jiayi Wu
- Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China
- Yangkai Fu
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Zhenxin Zeng
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Yinan Li
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Han Li
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Weijia Liao
- Department of Hepatobiliary Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China
- Maolin Yan
- Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China
- Maolin Yan
- Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital, Fuzhou, Fujian, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1187423
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
